Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVXNASDAQ:IMCRNASDAQ:MESONASDAQ:TVTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXABIVAX Société Anonyme$5.67-6.3%$6.37$4.77▼$14.71$359.59M0.29139,143 shs264,215 shsIMCRImmunocore$31.16-0.2%$29.01$23.15▼$49.05$1.56B0.75407,682 shs98,828 shsMESOMesoblast$10.85+0.2%$11.57$5.78▼$22.00$1.39B2.5271,621 shs106,288 shsTVTXTravere Therapeutics$15.84+0.9%$17.93$6.14▼$25.29$1.41B0.881.57 million shs1.43 million shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXABIVAX Société Anonyme-6.28%-5.66%-16.12%-29.83%-60.35%IMCRImmunocore-0.16%+2.60%+4.56%+4.14%-38.26%MESOMesoblast+0.18%-7.42%-2.31%-33.72%+37.52%TVTXTravere Therapeutics+0.89%-5.71%-5.12%-27.93%+141.46%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABVXABIVAX Société Anonyme2.4699 of 5 stars3.54.00.00.02.30.80.6IMCRImmunocore2.6362 of 5 stars4.30.00.00.02.54.20.0MESOMesoblast1.71 of 5 stars3.52.00.00.01.50.80.6TVTXTravere Therapeutics2.9456 of 5 stars4.42.00.00.03.30.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXABIVAX Société Anonyme 3.00Buy$31.00446.74% UpsideIMCRImmunocore 2.50Moderate Buy$58.1386.54% UpsideMESOMesoblast 3.00Buy$18.0065.90% UpsideTVTXTravere Therapeutics 2.87Moderate Buy$31.79100.67% UpsideCurrent Analyst Ratings BreakdownLatest ABVX, IMCR, TVTX, and MESO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025TVTXTravere TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/16/2025TVTXTravere TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$30.00 ➝ $30.005/8/2025IMCRImmunocoreOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$85.00 ➝ $86.005/2/2025TVTXTravere TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$30.00 ➝ $30.005/2/2025TVTXTravere TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$22.00 ➝ $23.004/30/2025ABVXABIVAX Société AnonymeJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$33.00 ➝ $33.004/23/2025TVTXTravere TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight4/14/2025IMCRImmunocoreJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$54.00 ➝ $50.004/14/2025TVTXTravere TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$47.00 ➝ $47.004/11/2025TVTXTravere TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform4/10/2025IMCRImmunocoreNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$71.00 ➝ $71.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXABIVAX Société AnonymeN/AN/AN/AN/A$3.37 per shareN/AIMCRImmunocore$333.58M4.68N/AN/A$7.42 per share4.20MESOMesoblast$5.67M244.51N/AN/A$4.21 per share2.58TVTXTravere Therapeutics$273.53M5.14N/AN/A$2.67 per share5.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXABIVAX Société Anonyme-$159.90MN/A0.00N/AN/AN/AN/AN/AN/AIMCRImmunocore-$55.29M-$0.43N/AN/AN/A-15.87%-12.84%-5.09%N/AMESOMesoblast-$87.96MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)TVTXTravere Therapeutics-$111.40M-$2.81N/AN/AN/A-137.90%-1,636.87%-55.95%8/7/2025 (Estimated)Latest ABVX, IMCR, TVTX, and MESO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025IMCRImmunocore-$0.35$0.10+$0.45$0.10$108.82 million$125.13 million5/1/2025Q1 2025TVTXTravere Therapeutics-$0.55-$0.47+$0.08-$0.47$77.44 million$81.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVXABIVAX Société AnonymeN/AN/AN/AN/AN/AIMCRImmunocoreN/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/ATVTXTravere TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXABIVAX Société Anonyme0.483.04N/AIMCRImmunocore1.033.783.76MESOMesoblast0.211.181.18TVTXTravere Therapeutics24.961.711.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXABIVAX Société Anonyme47.91%IMCRImmunocore84.50%MESOMesoblast1.43%TVTXTravere TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipABVXABIVAX Société AnonymeN/AIMCRImmunocore10.40%MESOMesoblast18.80%TVTXTravere Therapeutics4.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXABIVAX Société Anonyme6163.42 millionN/ANot OptionableIMCRImmunocore32050.07 million45.48 millionOptionableMESOMesoblast80127.78 million103.17 millionOptionableTVTXTravere Therapeutics46088.81 million75.12 millionOptionableABVX, IMCR, TVTX, and MESO HeadlinesRecent News About These CompaniesTravere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Nuveen Asset Management LLCMay 24 at 4:05 AM | marketbeat.comBronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Investors to Inquire about Securities InvestigationMay 23 at 10:00 AM | accessnewswire.comWoodline Partners LP Has $36.83 Million Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)May 23 at 6:16 AM | marketbeat.comBronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Reach OutMay 22 at 10:00 AM | accessnewswire.comTravere Therapeutics’ SWOT analysis: stock outlook amid regulatory reviewMay 21 at 11:56 PM | investing.comBronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Stockholders to Reach OutMay 21 at 10:00 AM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXMay 21 at 9:00 AM | accessnewswire.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Shares Acquired by Rafferty Asset Management LLCMay 21 at 5:41 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXMay 20, 2025 | prnewswire.comBronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Stockholders to ConnectMay 20, 2025 | accessnewswire.comTravere Therapeutics: Establishing A Position After Last Week's SelloffMay 20, 2025 | seekingalpha.comDeutsche Bank AG Lowers Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)May 19, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Reduces Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)May 19, 2025 | marketbeat.comSphera Funds Management LTD. Increases Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)May 18, 2025 | marketbeat.comNorthern Trust Corp Has $13.14 Million Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)May 18, 2025 | marketbeat.comTravere Therapeutics stock falls on FDA review setbackMay 16, 2025 | in.investing.comTravere flops as FDA accepts Filspari sNDA but plans AdComMay 16, 2025 | thepharmaletter.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Shares Purchased by Parkman Healthcare Partners LLCMay 16, 2025 | marketbeat.comTravere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGSMay 15, 2025 | businesswire.comAlgert Global LLC Invests $282,000 in Travere Therapeutics, Inc. (NASDAQ:TVTX)May 15, 2025 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Stock Position Reduced by Price T Rowe Associates Inc. MDMay 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABVX, IMCR, TVTX, and MESO Company DescriptionsABIVAX Société Anonyme NASDAQ:ABVX$5.67 -0.38 (-6.28%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$5.66 -0.01 (-0.26%) As of 05/23/2025 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Immunocore NASDAQ:IMCR$31.16 -0.05 (-0.16%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$31.16 +0.00 (+0.02%) As of 05/23/2025 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Mesoblast NASDAQ:MESO$10.85 +0.02 (+0.18%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$11.40 +0.55 (+5.02%) As of 05/23/2025 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Travere Therapeutics NASDAQ:TVTX$15.84 +0.14 (+0.89%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$15.92 +0.07 (+0.47%) As of 05/23/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
